Quarterly Results and Earnings Call Schedules, New Product Features, and FDA Approvals - Research Report on Infosys, FEI, Garmin, Cognex, and Cepheid

NEW YORK, July 10, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Infosys Limited (NYSE: INFY), FEI Company (NASDAQ: FEIC), Garmin Ltd. (NASDAQ: GRMN), Cognex Corporation (NASDAQ: CGNX), and Cepheid (NASDAQ: CPHD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Infosys Limited Research Report

On July 5, 2013, Infosys Limited (Infosys) announced that it will report results for its Q1 FY 2014 (period ended June 30, 2013) on July 12, 2013. Infosys informed that it will conduct its first conference call at 11:30 a.m. IST / 2:00 a.m. ET, and its second conference call at 8:30 a.m. ET / 6:00 p.m. IST, both on the same day, where the senior management will discuss the Company's performance and answer the questions from the participants. In Q4 FY 2013, the Company achieved revenues of INR10.5 million, representing a 18% YoY increase. Q4 FY 2013 diluted EPS was INR41.9, compared with INR40.5 in Q4 FY 2012. The Full Research Report on Infosys Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e5ea_INFY]

--

FEI Company Research Report

On July 3, 2013, FEI Company (FEI) announced the release of its Q2 2013 financial results on August 1, 2013, after the close of the financial market. The Company will host a conference call and hold a simultaneous webcast on the same day, at 2:00 p.m. PDT / 5:00 p.m. EDT, to discuss the results. Further, FEI also announced the management's participation in upcoming investor meetings: Fifth Annual CEO Investor Summit 2013 on July 10, 2013; Advanced Industrial Technologies Conference on August 13, 2013; and Microscopy and Microanalysis trade show from August 5 to August 8, 2013. The Full Research Report on FEI Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/fba8_FEIC]

--

Garmin Ltd. Research Report

On July 2, 2013, Garmin International Inc., a unit of Garmin Ltd. (Garmin), announced the DC 50 - a new and improved GPS dog tracking collar that according to Garmin, is even more robust and reliable than its previous models. "The new DC 50 has the features that will bring the benefits of GPS tracking to first-time users, and will convince existing Astro customers to upgrade," said Dan Bartel, Vice President of Worldwide Sales at Garmin. When paired with the Astro 320, Garmin informed that the system can track up to ten dogs per receiver at once, and will indicate the dog's distance, direction, and status. The DC 50 is the Company's latest innovation in its growing outdoor segment, which focuses on developing technologies to enhance user's outdoor experiences and their relationships with their dogs. The Full Research Report on Garmin Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0b26_GRMN]

--

Cognex Corporation Research Report

On June 20, 2013, Cognex Corporation (Cognex) introduced new lighting and optics features for its DataMan 300 series of industrial barcode readers. Cognex said that DataMan 300 became the preferred barcode reader due to its outstanding read rate performance and ease of use, and also claimed that with the introduction of the most flexible optics and lighting fixtures available on any image-based fixed-mount barcode reader, the demand for its product is set to continue. "As an added benefit, having the ability to optimize lights and optics for each application helps achieve the highest read rates possible," said Carl Gerst, Vice President and Business Unit Manager of ID Products at Cognex. The Full Research Report on Cognex Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/b326_CGNX]

--

Cepheid Research Report

On June 27, 2013, Cepheid (Cepheid) announced that it has received clearance from the FDA to market its Xpert MRSA/SA Blood Culture (BC) test for the detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) in blood culture bottles showing program-positive cocci in clusters in about one hour. "In the case of sepsis, one of the ten leading causes of death in the United States, test results must be available on-demand in order to have maximum impact on patient management. Our updated Xpert MRSA/SA BC test, along with the GeneXpert System, provides ability to obtain specific accurate results twenty four hours a day, seven days a week," said John Bishop, Chairman and CEO of Cepheid. The Full Research Report on Cepheid - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/02d2_CPHD]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports